Immunohistochemical assay for detection of cd3 and cd16
US-2016231322-A1 · Aug 11, 2016 · US
MonoMac-1 cells expressing CD16 and CD163
US11846629B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11846629-B2 |
| Application number | US-201716334808-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 20, 2017 |
| Priority date | Sep 20, 2016 |
| Publication date | Dec 19, 2023 |
| Grant date | Dec 19, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated monocyte, wherein the monocyte expresses CD16, CD163, and CD4. 2. The monocyte of claim 1 , wherein the monocyte is a MonoMac-1 cell. 3. A culture medium comprising the monocyte of claim 2 , phorbol-12-myristate-13-acetate (PMA), and lipopolysaccharide (LPS). 4. A culture medium comprising the monocyte of claim 2 , macrophage colony-stimulating factor (MCSF), and dexamethasone (DEX). 5. A culture medium comprising the monocyte of claim 2 , TNFα, and IFNγ.
Assignees
Inventors
Classifications
Macrophages, e.g. Kuepfer cells in the liver; Monocytes · CPC title
- G01N33/5047Primary
Cells of the immune system · CPC title
CD4 · CPC title
Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F) · CPC title
Molecules with a "CD"-designation not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11846629B2 cover?
- The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.
- Who is the assignee on this patent?
- Temple University—Of the Commonwealth System of Higher Education, Univ Tulane
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5047. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).